Compare Recursion Pharmaceuticals Inc (RXRX) vs Unum Group Common Stock (UNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Unum Group Common Stock — how do they compare? Recursion Pharmaceuticals Inc trades at $3.62 (market cap $2.02B), while Unum Group Common Stock trades at $91.42 (market cap $14.48B). The key difference: Unum Group Common Stock is far larger — about 7.2× Recursion Pharmaceuticals Inc's market cap, and Unum Group Common Stock pays a 2.21% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Unum Group Common Stock for 0 Days on average.
| RXRX | UNM | |
|---|---|---|
Market Cap | $2.02B | $14.48B |
Volume | 18,610,436 | 2,214,044 |
Sector | Health | Financials |
52-Week High | $6.79 | $96.57 |
52-Week Low | $2.84 | $70.66 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $1.54B | $18.04B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after beating expectations in previous quarters. Financials show significant losses with -961.97% net income margin and $644.76M net loss in 2025, though revenue grew to $74.26M. Recent strategic partnerships with Tempus and Roche highlight AI-driven drug discovery focus.
Outlook remains speculative with high-risk/high-reward profile. The AI drug discovery platform shows promise through partnerships, but profitability challenges and cash burn require careful monitoring. Analyst consensus leans cautious with 40% buy ratings amid substantial operational losses. Key catalysts include pipeline advancements and partnership milestones through 2028.
Unum Group (UNM) trades at $92.05, down 0.5% with neutral technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Analyst consensus is positive with 50% buy ratings and a $101 price target representing 9.7% upside. The company maintains stable profitability with 5.31% net margin and recently announced a $1 billion share repurchase program to enhance shareholder returns.
UNM presents a balanced investment case with strong institutional support and shareholder-friendly capital returns, though earnings consistency remains a concern. The stock trades at reasonable valuations (P/E 21.36, P/S 1.15) with potential upside to analyst targets. Key risks include premium growth sustainability and claims experience volatility in the insurance operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Unum Group Common Stock
Unum Group provides workplace benefits, including disability, life, accident, critical illness, dental, and vision insurance, along with leave management services. It serves employers through its Unum US, Unum International, and Colonial Life segments, distributing coverage via brokers and independent agents.
Read more on UNM →
